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591randomized controlled trials should be that DES are associated
with increased mortality (17 deaths of 113 DES and 4 deaths of
89 bare-metal stents; p 0.027). This is in contradiction to the main
conclusion of this manuscript that “DES use was associated with
improved mortality.” It is hard, if not impossible, to justify such a
conclusion even if it is supported by nonrandomized cohort trials data
when the randomized controlled trials data are contradictory. I believe
the message to the readers from this manuscript is misleading,
therefore, I believe the entire manuscript should be rewritten with the
correct analysis and conclusions.
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Reply
We would like to thank the authors of the letters for their
interest in our paper (1). We agree that the RRISC (Reduction
f Restenosis In Saphenous vein grafts with Cypher sirolimus-
luting stent) and DELAYED RRISC (Death and Events at
ong-term follow-up AnalYsis: Extended Duration of the
eduction of Restenosis In Saphenous vein grafts with Cypher
tent) trials included the same patients (2,3). On the basis of the
re-specified criteria for the meta-analysis, we included all
ublished trials on the use of drug-eluting stents (DES) versus
are-metal stents (BMS) in vein graft percutaneous coronary
ntervention (PCI). Because the included studies were weighted
n the basis of study size, and because this particular study was
mall in size (only 75 patients), we did not anticipate any
ignificant impact of this strategy on the overall conclusions.
e analyzed the data with and without inclusion of thehort-term RRISC data and found no significant differences inthe conclusions. Drug-eluting stent use was associated with
reduced mortality when early and delayed RRISC data were
included (odds ratio [OR]: 0.72; 95% confidence interval [CI]: 0.58
to 0.89), and there was no significant difference when the early
RRISC data were excluded (OR: 0.72; 95% CI: 0.58 to 0.89) (Fig.
1A). Similarly, DES use—including early RRISC data—led to
reduced target vessel revascularization (OR: 0.56; 95% CI: 0.40 to
0.77). Excluding these data, there was no significant change in the
estimated benefit of DES on target vessel revascularization (OR:
0.58; 95% CI: 0.42 to 0.77) (Fig. 1B). Identical conclusions were
made when other adverse outcomes were analyzed with and
without inclusion of early RRISC events.
Despite the statistically significant reduction in mortality
associated with DES in our overall analysis, we clearly stated in
the discussion that this is possibly caused by selection bias. We
emphasized that this finding was primarily noted in the cohort
trials and not in randomized trials, hence reinforcing the notion
that it might have been driven by interventional operators
selecting healthier patients to implant DES. We referenced the
work by Shishehbor et al. (4), who made similar observations.
Because of that concern, we opted not to state that mortality
benefit in our final conclusions paragraph in the published paper
(1). The meta-analysis of the body of literature supports the fact
that DES use in vein graft PCI is safe and not associated with
increased risk of adverse events or mortality, despite the
limitations and as noted in the conclusions paragraph. This
remains our conclusion and that of others who performed
similar meta-analyses (5–9).
We agree with the criticism of the multiplicity of meta-
analyses performed on the same subject. We believe this is the
effect of the publication and peer-review process as it works
today. It is likely that—given the time it takes from writing the
manuscript to submission, review, and response to editorial
revisions—most of these manuscripts were making their way
through the process at different journals at the same time, thus
making it difficult to know that each of these papers was in press. As
stated, this can be avoided with the creation of a central repository of
systematic reviews and meta-analyses for authors to submit to as well as
be aware of similar projects in development. Given the number of
independent journals dedicated to cardiology and its subspecialties, this
might not be an easy task.
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Use of Cardiac Computed
Tomography Prior to Percutaneous
Coronary Sinus Device Placement
for the Treatment of
Mitral Regurgitation
We would like to congratulate Harnek et al. (1) for showing
hat percutaneous implantation of the Monarc device (Edwards
ifesciences, Irvine, California) in the coronary sinus is not only
easible but also effectively reduces mitral regurgitation. The
nvestigators found that computed tomography (CT) docu-
ented the passage of the great cardiac vein (GCV) over an
btuse marginal artery in 55% of patients. The obtuse marginal
rtery was associated with angiographic coronary artery com-
ression in 15 patients and with myocardial infarction in 2
atients. In contrast, the coronary sinus/great cardiac vein
CS/GCV) did not pass over a major obtuse marginal artery in
9 patients, none of whom developed coronary artery compres-
ion. This study demonstrates that coronary artery compression
ay occur in patients in whom the GCV passes over a coronary
rtery. Cardiothoracic surgeons have appreciated for years that
urgical mitral valve annuloplasty may result in ischemia from
njury to the adjacent left circumflex artery (LCX) (2,3).
The potential for external coronary artery compression when
he CS/GCV runs over the obtuse marginal epicardial vessels
merged as the most important consideration for use of this
evice. The present study by Harnek et al. (1) shows that
oninvasive screening with CT is able to identify those patients
n whom the obtuse marginal vessels course under the CS/GCV
nd are therefore at risk for this complication. Accurate
re-procedural understanding of the CS/GCV anatomy as itrelates to the mitral valve, specifically the posterior mitral leaflet
and the LCX with its obtuse marginal (OM) branches, is vital
for this approach to be efficient and successful. We previously
developed a systematic method for describing the CS/GCV and
LCX/OM relationship with cardiac CT data (4). We found that a
large proportion of patients have the LCX/OM arterial distribution
traveling under the CS/GCV, and we found that this relationship
depends on coronary arterial dominance. In addition, we found that the
first OMwas under the CS/GCV in 26% to 61% of patients, depending
on the coronary dominance, compared with the second OM that was
under the CS/GCV in 13% to 28% of patients. It should also be noted
that a posterolateral branchmight also course under the CS in up to 53%
of patients, and thus may also be a potential artery that could be
jeopardized with a CS-based annuloplasty device.
Cardiac CT imaging of the CS/GCV using an organized
method should be considered an excellent tool to evaluate the
anatomic course of the coronary arteries in patients being evaluated
for percutaneous CS devices. The potential benefits of a minimally
invasive option to treat mitral regurgitation with percutaneous
transvenous catheter-based deployment of such annuloplasty de-
vices will need prospective studies to demonstrate that procedural
and late complications can indeed be avoided by using an image
guidance approach with cardiac CT.
Ambarish Gopal, MD
Matthew J. Budoff, MD
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Reply
We thank Dr. Gopal and colleagues for their interest in our paper
(1) and agree that computed tomography is an important imaging
modality to screen patients at risk for coronary compression before
